Lexeo Therapeutics, Inc. Common Stock
HealthcareNASDAQ:LXEO · NASDAQ Global Market
+$0.17 today
Vol 0.62M · Avg 0.85M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-40.5%
avg 8.9%
ROIC
-42.9%
avg -50.6%
ROA
-37.2%
avg -44.5%
Analysis
ROA is currently the strongest return metric at -37.2% versus its period average of -44.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Jose Manuel Otero | Chief Operating Officer | $2.99M | — | 47 | $130,088.00 | 0.17% |
Eric Adler | Advisor | $2.71M | — | 52 | $72,646.00 | 0.09% |
R. Nolan Townsend | Chief Executive Officer & Director | $991,470.00 | — | 45 | $336,764.00 | 0.43% |
Louis Tamayo | Chief Financial Officer & Principal Accounting Officer | $638,897.00 | — | 49 | $226,665.00 | 0.29% |
Ronald G. Crystal | Co-Founder, Chief Scientific Advisor & Member of Scientific Advisory Board | — | — | — | — | — |
Jordan Baumhardt | Vice President of Corporate Development | — | — | — | — | — |
Keith Wonnacott | Senior Vice President of Regulatory Affairs | — | — | — | — | — |
Narinder Bhalla FACC FSCAI | Chief Medical Officer | — | — | 62 | $297,000.00 | 0.38% |
Leslie DiRisio | Senior Vice President of Development Operations | — | — | — | — | — |
Ryan McHenry | Vice President & Corporate Controller | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
26
$725,171.42
Net Sentiment
$725,171.42
Net selling
Most Active
Otero Jose Manuel
7 transactions
1–10 of 26
Analysis
Insiders reported 0 buys worth $0.00 and 26 sells worth $725,171.42 over the last 12 months. That adds up to net selling of $725,171.42. Otero Jose Manuel was the most active insider with 7 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Capricor Therapeutics, Inc.
NASDAQ:CAPR
$1.18B
Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ:CTNM
$444.15M
DBV Technologies S.A.
NASDAQ:DBVT
$416.60M
Vanda Pharmaceuticals Inc.
NASDAQ:VNDA
$353.00M
Kyverna Therapeutics, Inc.
NASDAQ:KYTX
$352.74M
Silence Therapeutics plc
NASDAQ:SLN
$316.00M
Amarin Corporation plc
NASDAQ:AMRN
$315.21M
Larimar Therapeutics, Inc.
NASDAQ:LRMR
$296.96M
Voyager Therapeutics, Inc.
NASDAQ:VYGR
$211.47M
Mereo BioPharma Group plc
MREO
$48.68M
Who manages LXEO?
Lexeo Therapeutics, Inc. Common Stock (LXEO) lists 10 active executives. The top listed executive is R. Nolan Townsend, Chief Executive Officer & Director.
Are LXEO insiders buying or selling?
Recent insider activity shows net buying of $26.04M.
Explore More
Continue the stock analysis
Jump to another research area for this company.